Monitoring the safety of nilotinib in patients with chronic myeloid leukemia

Pendovska, Marija and Naumovska, Zorica and Panovska, Irina and Pavkovic, Marica and Kalcev, Goce and Zisovska, Elizabeta and Mihajloska, Evgenija and Filkova, Sanja and Suturkova, Ljubica (2019) Monitoring the safety of nilotinib in patients with chronic myeloid leukemia. Macedonian pharmaceutical bulletin, 65 (2). pp. 67-72. ISSN 1409 - 8695

Text Pharmaceutical bullein - Zisovska, 65_2_008.pdf - Published Version Download (665kB)

Abstract

The aim of the study was to evaluate the safety profile of nilotinib administered to chronic myeloid leukemia (CML) at patients. The
study was conducted from March 2018 to May 2019 and it included 20 patients with CML in chronic phase. Of these 20 patients, 17 had
previously been treated with imatinib and 3 with hydroxyurea. The mean duration of treatment with Nilotinib was 6.75 months. In nine
patients treated with nilotinib (400 mg), 55% complained of fatigue, 33% of headache and 22.2% of pruritus. In five patients treated with
Nilotinib (600 mg), 20% complained of headache, 40% of fatigue and 20% of pruritus. In addition, in six patients treated with nilotinib
(800 mg), 50% complained of headache and fatigue, 17% with pruritus and visual disorder was observed in 20% of cases. In the study,
the adverse reactions were observed between the age of 20 and 40 and it was 7.1%, in contrast to the group of patients between the age of
40 and 60 where the incidence of adverse reactions was 21.42%. The incidence of adverse reactions in patients in the age group over 60
years it was 57.1%. In terms of gender, the incidence of adverse reactions was equal to 50% for both men and women. In conclusion, this
study showed that treatment with nilotinib was well tolerated, with adverse reactions of an easy degree. Future evaluation is necessary in
order to understanding the adverse reaction of nilotinib in comparison with other tyrosine kinase inhibitors.
Keywords: nilotinib, pharmacovigilance, safety, chronic myeloid leukemia

Item Type:	Article
Subjects:	Medical and Health Sciences > Clinical medicine
Divisions:	Faculty of Medical Science
Depositing User:	Elizabeta Zisovska
Date Deposited:	14 Jun 2021 06:11
Last Modified:	14 Jun 2021 06:11
URI:	https://eprints.ugd.edu.mk/id/eprint/28174

Actions (login required)

View Item